A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.

By E. Cunningham, A. Adamis, M. Altaweel, L. Aiello, N. Bressler, D. D’Amico, M. Goldbaum, D. Guyer, B. Katz, Manju Patel and 1 more. Ophthalmology (Rochester, Minn.), 2005

602 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology, Ophthalmology

View Paper: https://www.semanticscholar.org/paper/ade16000fcbbf4725b0250a6a531f8c9375933b6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. N. Bhagat
2. M. Hartnett
3. R. Grigorian
4. J. Penn
5. Ruth B. Caldwell
6. R. W. Caldwell
7. A. Tutela
8. M. Zarbin

In Ophthalmology

1. N. Bhagat
2. R. Grigorian
3. A. Tutela
4. M. Zarbin

Citations in the corpus

• Vascular endothelial growth factor in eye disease. (2008, background): “…injections of Macugen had better visual acuity outcomes, were more likely to show reduction in central retinal thickness and were deemed less likely to need additional therapy with photocoagulation at follow-up as compared with the sham-injected control subjects (Cunningham et al., 2005).”
• Diabetic macular edema: pathogenesis and treatment. (2009, background): “3-mg dose is the most efficacious; however, the limitation of this study is a lack of power to detect the difference between different doses of pegaptanib.(129) Phase III trials are underway.”
• Current approaches in SELEX: An update to aptamer selection technology. (2015, background): “Macugen was the first aptamer to enter clinical trials and obtain FDA approval in 2005 for treatment of retinopathies (Cunningham et al., 2005).”